These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 9125048

  • 1. Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies.
    Wu L, Forghani B.
    Arch Virol; 1997; 142(2):349-62. PubMed ID: 9125048
    [Abstract] [Full Text] [Related]

  • 2. Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE).
    Garcia-Valcarcel M, Fowler WJ, Harper DR, Jeffries DJ, Layton GT.
    Vaccine; 1997; 15(6-7):709-19. PubMed ID: 9178473
    [Abstract] [Full Text] [Related]

  • 3. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus.
    Fowler WJ, Garcia-Valcarcel M, Hill-Perkins MS, Murphy G, Harper DR, Jeffries DJ, Burns NR, Adams SE, Kingsman AJ, Layton GT.
    Virology; 1995 Dec 20; 214(2):531-40. PubMed ID: 8553555
    [Abstract] [Full Text] [Related]

  • 4. Stability of a varicella-zoster virus glycoprotein E epitope.
    Vafai A, Forghani B, Kilpatrick D, Ling J, Shankar V.
    Arch Virol; 2000 Dec 20; 145(1):85-97. PubMed ID: 10664408
    [Abstract] [Full Text] [Related]

  • 5. Epitopes functional in neutralization of varicella-zoster virus.
    Forghani B, Dupuis KW, Schmidt NJ.
    J Clin Microbiol; 1990 Nov 20; 28(11):2500-6. PubMed ID: 1701445
    [Abstract] [Full Text] [Related]

  • 6. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus.
    Kutinová L, Hainz P, Ludvíková V, Maresová L, Nĕmecková S.
    Virology; 2001 Feb 15; 280(2):211-20. PubMed ID: 11162835
    [Abstract] [Full Text] [Related]

  • 7. Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein.
    Vafai A.
    Vaccine; 1994 Nov 15; 12(14):1265-9. PubMed ID: 7531921
    [Abstract] [Full Text] [Related]

  • 8. Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay.
    Liu J, Ye X, Jia J, Zhu R, Wang L, Chen C, Yang L, Wang Y, Wang W, Ye J, Li Y, Zhu H, Zhao Q, Cheng T, Xia N.
    Sci Rep; 2016 Feb 08; 6():20577. PubMed ID: 26853741
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells.
    Haumont M, Jacquet A, Massaer M, Deleersnyder V, Mazzu P, Bollen A, Jacobs P.
    Virus Res; 1996 Feb 08; 40(2):199-204. PubMed ID: 8725116
    [Abstract] [Full Text] [Related]

  • 11. Glycoprotein E-Displaying Nanoparticles Induce Robust Neutralizing Antibodies and T-Cell Response against Varicella Zoster Virus.
    Wang H, Zhang S, Xue W, Zeng Y, Liu L, Cui L, Liu H, Zhang Y, Chen L, Nie M, Zhang R, Chen Z, Hong C, Zheng Q, Cheng T, Gu Y, Li T, Xia N, Li S.
    Int J Mol Sci; 2024 Sep 12; 25(18):. PubMed ID: 39337359
    [Abstract] [Full Text] [Related]

  • 12. Recombinant glycoprotein E produced in mammalian cells in large-scale as an antigen for varicella-zoster-virus serology.
    Thomsson E, Persson L, Grahn A, Snäll J, Ekblad M, Brunhage E, Svensson F, Jern C, Hansson GC, Bäckström M, Bergström T.
    J Virol Methods; 2011 Jul 12; 175(1):53-9. PubMed ID: 21540058
    [Abstract] [Full Text] [Related]

  • 13. Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response.
    Padilla JA, Grose C.
    Arch Virol Suppl; 2001 Jul 12; (17):27-39. PubMed ID: 11339548
    [Abstract] [Full Text] [Related]

  • 14. Differential neutralizing antibody responses to varicella-zoster virus glycoproteins B and E following naked DNA immunization.
    Massaer M, Haumont M, Garcia L, Mazzu L, Bollen A, Jacobs P, Jacquet A.
    Viral Immunol; 1999 Jul 12; 12(3):227-36. PubMed ID: 10532651
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
    Kitamura K, Namazue J, Campo-Vera H, Ogino T, Yamanishi K.
    Virology; 1986 Feb 12; 149(1):74-82. PubMed ID: 2418583
    [Abstract] [Full Text] [Related]

  • 17. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E.
    Hasan UA, Harper DR, Wren BW, Morrow WJ.
    Vaccine; 2002 Jan 31; 20(9-10):1308-15. PubMed ID: 11818149
    [Abstract] [Full Text] [Related]

  • 18. Role of neutralizing antibody in the pathogenesis of zoster and the correlation of severity with anti-gE: gI antibody response.
    Matsuo K, Honda M, Shiraki K.
    J Dermatol; 2003 Feb 31; 30(2):109-15. PubMed ID: 12692377
    [Abstract] [Full Text] [Related]

  • 19. Immunological characterisation of glycoprotein E of Aujeszky's disease virus.
    Morenkov OS, Fodor N, Sobko YA, Fodor I.
    Virus Res; 1997 Sep 31; 51(1):65-79. PubMed ID: 9381796
    [Abstract] [Full Text] [Related]

  • 20. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.
    Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, Van Regenmortel MH.
    Virology; 1992 Apr 31; 187(2):480-91. PubMed ID: 1372140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.